These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 8758090)

  • 21. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
    Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
    Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NECT trial: more than a small victory over sleeping sickness.
    Opigo J; Woodrow C
    Lancet; 2009 Jul; 374(9683):7-9. PubMed ID: 19559477
    [No Abstract]   [Full Text] [Related]  

  • 23. Production of sleeping-sickness treatment.
    Pécoul B; Gastellu M
    Lancet; 1999 Sep; 354(9182):955-6. PubMed ID: 10489988
    [No Abstract]   [Full Text] [Related]  

  • 24. Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola.
    Robays J; Raguenaud ME; Josenando T; Boelaert M
    Trop Med Int Health; 2008 Feb; 13(2):265-71. PubMed ID: 18304274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy for second-stage Human African trypanosomiasis.
    Lutje V; Seixas J; Kennedy A
    Cochrane Database Syst Rev; 2010 Aug; (8):CD006201. PubMed ID: 20687080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness.
    Khonde N; Pépin J; Mpia B
    Trans R Soc Trop Med Hyg; 1997; 91(2):212-3. PubMed ID: 9196773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eflornithine for the treatment of human African trypanosomiasis.
    Burri C; Brun R
    Parasitol Res; 2003 Jun; 90 Supp 1():S49-52. PubMed ID: 12811548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in sleeping sickness therapy.
    Van Nieuwenhove S
    Ann Soc Belg Med Trop; 1992; 72 Suppl 1():39-51. PubMed ID: 1417168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
    Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P
    J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy for second-stage human African trypanosomiasis.
    Lutje V; Seixas J; Kennedy A
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD006201. PubMed ID: 23807762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unusual MRI Findings in African
    Boukobza M; Lariven S; Houzé S; Laissy JP
    Am J Trop Med Hyg; 2020 Jan; 102(1):5-6. PubMed ID: 31971136
    [No Abstract]   [Full Text] [Related]  

  • 32. Human African trypanosomiasis caused by Trypanosoma brucei gambiense: The first case report in China.
    Chen N; Jin K; Xu J; Zhang J; Weng Y
    Int J Infect Dis; 2019 Feb; 79():34-36. PubMed ID: 30423460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001.
    Pépin J; Mpia B
    Emerg Infect Dis; 2005 Jun; 11(6):921-7. PubMed ID: 15963288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.
    Balasegaram M; Young H; Chappuis F; Priotto G; Raguenaud ME; Checchi F
    Trans R Soc Trop Med Hyg; 2009 Mar; 103(3):280-90. PubMed ID: 18947846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The phenomenon of treatment failures in Human African Trypanosomiasis.
    Brun R; Schumacher R; Schmid C; Kunz C; Burri C
    Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Winterbottom's sign and hypertrophic cardiomyopathy.
    Stephan C; Just-Nuebling G; Fichtlscherer S; Kriener S; Brodt HR
    Scand J Infect Dis; 2002; 34(7):544-5. PubMed ID: 12195887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
    Priotto G; Kasparian S; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Karunakara U
    Clin Infect Dis; 2007 Dec; 45(11):1435-42. PubMed ID: 17990225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis.
    Simarro PP; Franco J; Diarra A; Postigo JA; Jannin J
    Parasitology; 2012 Jun; 139(7):842-6. PubMed ID: 22309684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Agents for the treatment of African sleeping sickness. Those developed in the last century].
    Schlitzer M
    Pharm Unserer Zeit; 2009; 38(6):552-8. PubMed ID: 19862727
    [No Abstract]   [Full Text] [Related]  

  • 40. Killer coma: the evolving story of sleeping sickness treatment.
    Lancet; 2010 Jan; 375(9709):93. PubMed ID: 20109869
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.